Mayordomo 1995.

Study characteristics
Methods	Placebo‐controlled, industry‐funded, single‐center trial
Participants	Adults; mixed tumors; ANC < 0.5 x 109/L
Interventions	G‐CSF (filgrastim) 5 mcg/kg IV OR GM‐CSF (molgramostim) 5 mcg/kg IV ATB: Amikacin + Ceftazidime
Outcomes	Overall mortality Infection‐related mortality People with hospitalization for greater than 10 days Bone and joint pain or flu‐like symptoms Time to neutrophil recovery
Notes	Hospital discharge criteria: afebrile for at least 48 hours; ANC at least 1000/mm3 Duration of grade IV neutropenia reported as median number of days of neutropenia ANC < 0.5 x 109/L
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	High risk	Description of method of sequence generation not provided
Allocation concealment (selection bias)	Low risk	Sealed envelopes were used
Blinding (performance bias and detection bias) All outcomes	High risk	There was no blinding
Blinding of participants and personnel (performance bias) All outcomes	High risk	There was no blinding
Blinding of outcome assessment (detection bias) All outcomes	High risk	There was no blinding
Incomplete outcome data (attrition bias) All outcomes	Low risk	ITT analysis used, withdrawals are described
Other bias	Low risk	Prespecified values of sample size, alpha and beta errors were provided